



TriMark Publications

December 2004  
Volume: TMRKEY04-1204

# KEY DIAGNOSTIC TESTING MARKETS *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overview and Market Drivers

**TABLE OF CONTENTS**

1.	Overview	10
1.1	Objectives	10
1.2	Content and Scope	10
1.3	Methodology	11
1.4	Executive Summary	12
1.4.1	Glucose Monitoring	13
1.4.2	Coagulation	13
1.4.3	Rapid Cardiac Markers	14
1.4.4	Drugs of Abuse Screening	14
1.4.5	Infectious Disease Testing	15
1.4.5.1	Campylobacter	15
1.4.5.2	Chlamydia	15
1.4.5.3	Clostridium difficile	15
1.4.5.4	Cryptosporidium	15
1.4.5.5	Dengue Fever	15
1.4.5.6	Entamoeba histolytica	15
1.4.5.7	Giardia Species	15
1.4.5.8	Helicobacter pylori	15
1.4.5.9	Hepatitis Testing	16
1.4.5.10	HIV	16
1.4.5.11	Rapid Influenza Testing	16
1.4.5.12	Mononucleosis	16
1.4.5.13	Streptococcus Testing	16
1.4.6	Cholesterol Testing	16
1.4.7	Tumor Markers	16
1.4.7.1	Prostate Specific Antigen (PSA) Testing	17
2.	Introduction	18
2.1	Basic Structure and Perspectives	18
2.2	Global Diagnostic Products Industry Status and Prognosis	18
2.3	Size, Structure and Growth of the Industry	19
2.3.1	Current Market Size	19
2.3.2	Market Segments	20
2.3.2.1	Clinical Chemistry	20
2.3.2.2	Immunoassays	21
2.3.2.3	Nucleic Acid Arrays	22
2.3.2.4	Coagulation Tests	23
2.3.2.5	Critical Care Testing	24
2.4	Trends and Forces Driving the Industry	24
2.4.1	Global Demographics	24
2.4.2	Healthcare Delivery and Disease Management	25
2.4.3	Technological Innovation	26
2.5	Alternate Site Diagnostic Testing	26
3.	Market Analysis	30
3.1	Glucose Monitoring	30
3.1.1	Market Size	30
3.1.2	Competitive Landscape	31
3.1.2.1	LifeScan, Inc.	31
3.1.2.2	Roche Diagnostics	33
3.1.2.3	Bayer	33
3.1.2.4	Abbott Diagnostics	35
3.1.2.5	HemoCue	35

3.1.2.6	Technical Chemicals & Products	35	
3.1.2.7	GDS Technology	35	
3.1.2.8	LXN Corp.	35	
3.1.2.9	Cholestech	35	
3.1.2.10	Alternate Glucose Monitoring Products	35	
3.2	Rapid Coagulation Tests	37	
3.2.1	Roche Diagnostics	39	
3.2.2	Avocet Medical	40	
3.2.3	International Technidyne Corporation	40	
3.2.4	Cardiovascular Diagnostics	41	
3.2.5	Other Companies	42	
3.3	Rapid Cardiac Markers	43	
3.3.1	The Companies	44	
3.3.1.1	Spectral Diagnostics	44	
3.3.1.2	Biosite Diagnostics	44	
3.3.1.3	Roche Diagnostics	45	
3.3.1.4	Beckman Coulter, Inc.	46	
3.3.1.5	First Medical	46	
3.3.1.6	ANI Biotech	46	
3.3.1.7	Chembio Diagnostics	46	
3.3.1.8	Abbott Diagnostics	46	
3.3.1.9	TOSOH Medics, Inc.	47	
3.3.1.10	Roche Diagnostics	47	
3.3.1.11	Bayer Diagnostics	47	
3.3.1.12	Diagnostic Products	47	
3.3.1.13	Dade Behring	48	
3.3.2	BNP Testing and Congestive Heart Failure	48	
3.3.2.1	Differential Diagnosis	48	
3.3.2.2	Staging of Heart Failure	48	
3.3.2.3	Circulating Marker of CHF	49	
3.3.2.4	Commercial Assays for BNP and NT-proBNP	49	
3.3.2.5	Clinical Applications of BNP	50	
3.3.2.6	Correlation with NYHA Classifications	50	
3.3.2.7	Correlation with LVSD	50	
3.3.2.8	Prediction of Adverse Outcomes in Acute and Chronic Heart Disease	51	
3.3.2.9	Selection and Monitoring of Therapy	51	
3.3.2.10	Summary	52	
3.4	Drugs of Abuse Screening	52	
3.4.1	Major Players	57	
3.4.1.1	Bayer Diagnostics	57	
3.4.1.2	Biosite Diagnostics	57	
3.4.1.3	Dade Behring Syva (POC Technologies)	58	
3.4.1.4	Roche Diagnostics	59	
3.4.1.5	BioScan Screening Systems, Inc.	60	
3.4.1.6	American Bio Medica Corp.	60	
3.4.1.7	Instant Diagnostics, Inc.	61	
3.4.1.8	Worldwide Medical	62	
3.4.1.9	STC Diagnostics	62	
3.4.1.10	DynaGen, Inc.	63	
3.4.1.11	Avitar Technologies	63	
3.4.1.12	Princeton BioMeditech	63	
3.4.1.13	Abbott Diagnostics	64	
3.4.1.14	Diagnostic Products	64	
3.5	Infectious Disease Testing	65	
3.5.1	Campylobacter	65	
3.5.2	Chlamydia	66	

3.5.3	Clostridium difficile	66	
3.5.4	Cryptosporidium	67	
3.5.5	Dengue Fever	67	
3.5.6	Entamoeba histolytica		68
3.5.7	Giardia Species	68	
3.5.8	Helicobacter pylori	69	
3.5.9	Hepatitis Testing	71	
3.5.9.1	Overview	71	
3.5.9.2	Hepatitis Serologic Markers and Nucleic Acid Testing		72
3.5.9.2.1	Hepatitis A Virus	72	
3.5.9.2.2	Hepatitis B Virus	72	
3.5.9.2.3	Hepatitis C Virus	75	
3.5.9.2.4	Hepatitis D Virus	77	
3.5.9.2.5	Hepatitis E virus	77	
3.5.9.2.6	Hepatitis B Virus/Hepatitis C Virus Viral Load and Drug Resistance		78
3.5.9.3	Companies and Hepatitis Tests	78	
3.5.9.3.1	Home Access Health	78	
3.5.9.3.2	Orgenics	78	
3.5.9.3.3	Princeton BioMeditech Corp.	78	
3.5.9.3.4	Chembio Diagnostics	78	
3.5.9.3.5	Abbott Diagnostics	79	
3.5.9.3.6	Beckman Coulter	79	
3.5.9.3.7	Roche Diagnostics	79	
3.5.9.3.8	Bayer Diagnostics	80	
3.5.9.3.9	Diagnostic Products Corp.	80	
3.5.9.3.10	LabCorp	80	
3.5.10	HIV	82	
3.5.10.1	Blood Versus Oral Fluid/Urine Testing	84	
3.5.10.2	Life Insurance Companies and Urine Testing		86
3.5.10.3	HIV Outside the U.S.	86	
3.5.10.4	Markets Analysis	87	
3.5.10.5	Calypte Biomedical Corp.	89	
3.5.10.6	Orgenics	90	
3.5.10.7	Princeton BioMeditech Corp.	90	
3.5.10.8	Chembio Diagnostics	90	
3.5.10.9	OraSure Technologies	90	
3.5.10.10	Ely Labs	91	
3.5.10.11	Abbott Diagnostics	91	
3.5.10.12	Beckman Coulter	91	
3.5.10.13	Bayer Diagnostics	92	
3.5.10.14	Celera Diagnostics	92	
3.5.10.15	Roche Diagnostics	92	
3.5.10.16	MedMira, Inc.	93	
3.5.10.17	Summary and Recent Developments		93
3.5.11	Rapid Influenza Testing	94	
3.5.12	Mononucleosis	94	
3.5.12.1	Quidel	95	
3.5.12.2	Worldwide Medical	95	
3.5.12.3	Genzyme Diagnostics		95
3.5.12.4	Wyntek Diagnostics	95	
3.5.12.5	Wampole Laboratories		95
3.5.12.6	GenBio	95	
3.5.12.7	Other Companies in the Market	95	
3.5.13	Rubella	96	
3.5.14	Salmonella	96	
3.5.15	Shiga-Toxin E. coli	96	

3.5.16	Staphylococcus	96	
3.5.17	Streptococcus Testing	97	
3.5.17.1	Quidel	97	
3.5.17.2	Other Companies	98	
3.5.18	TB and Lyme Disease	98	
3.6	Cholesterol Testing	98	
3.6.1	Consumer Market Disposable Testing (Single-Use)	99	
3.6.2	Instrument/Disposable Strip (Multiple-Use Instruments)	100	
3.6.3	Homocysteine	100	
3.6.4	Companies in the Market	100	
3.6.4.1	Cholestech	100	
3.6.4.2	Lifestream Technologies	100	
3.6.4.3	Actimed Laboratories	101	
3.6.4.4	Drew Scientific	101	
3.6.4.5	International Medical Innovations	101	
3.7	Tumor Markers	102	
3.7.1	Market Description	102	
3.7.2	Clinical Diagnostic Serum-Based Cancer Markers	103	
3.7.2.1	Beckman Coulter	104	
3.7.2.2	Fujirebio, Inc.	104	
3.7.2.3	Abbott Diagnostics	104	
3.7.2.4	Beckman Coulter	104	
3.7.2.5	Roche Diagnostics	105	
3.7.3	PSA Testing	105	
3.7.3.1	TOSOH Medics, Inc.	105	
3.7.3.2	Bayer Diagnostics	106	
3.7.3.3	Diagnostic Products	106	
3.7.4	Other Markers	106	
4.	Business Trends	108	
4.1	Industry Consolidation	108	
4.2	Breadth of Product Offering	109	
4.3	Government Regulation of Medical Devices	109	
4.3.1	Importing/Exporting Medical Devices Into and Out of the U.S.	111	
4.3.2	U.K. Regulations	112	
4.3.3	EU Regulations	113	
4.3.4	Japanese Regulations	115	
4.4	Clinical Laboratory Improvement Act (CLIA)	115	
5.	Patient Management Trends	117	
5.1	Trends in Patient Care and Reimbursement	117	
5.1.1	A Curious System	118	
5.1.2	The Case of Tumor Markers	119	
5.1.3	Other Federal Policy Considerations	120	
5.2	Alternate Site Testing	120	
5.3	Moderators of Growth	120	
5.3.1	Quality Assurance Issues	120	
5.3.2	Political Control	121	
5.3.3	Regulatory Requirements	121	
5.3.4	Record Keeping and Data Management	121	
5.3.5	Finance	121	
5.3.6	Emergency Room Admissions and Trends	122	
5.3.7	Attitudes of Critical Care Nurses and Physicians	122	
5.4	Personnel for POC Testing	122	
5.5	Locations of POC for Patient Care	123	
5.6	Focused Testing	124	

5.7	Satellite Facilities	124	
5.8	POC Testing	124	
5.9	Hospital Labs	125	
5.10	Doctor's Office Testing	126	
5.11	Home Care	127	
5.12	Non-traditional Collection for Sample Testing	127	
6.	Technology Trends	128	
6.1	Sensor Systems for Diagnostic Applications	128	
6.2	Glucose Measurements	129	
6.2.1	Different Types of Diabetes	130	
6.2.2	Public Health Impact of Diabetes	130	
6.2.3	Diagnosis of Diabetes	130	
6.2.4	Hypoglycemia	131	
6.2.5	Glucose Test Methods	131	
6.3	Cholesterol Testing	132	
6.4	The New Paradigm	132	
6.5	Consolidated Workstations and Modularity	133	
6.6	Automation and Robotics	133	
6.7	Laboratory Information Systems (LIS)	134	
6.8	Biosensor Technology	134	
6.8.1	Microfluidic and Biosensor Chip Technology	135	
6.9	Protein Sequencing	136	
6.10	DNA Sequencing	136	
6.11	The Human Genome Project	137	
6.12	Liquid Phase Chromatography	138	
6.13	Polymerase Chain Reaction	138	
6.14	Capillary Electrophoresis	139	
6.15	Proteomics	139	
7.	Data Management Issues	141	
7.1	Wireless Local Area Networks	141	
7.2	Wireless Technology	141	
7.3	Wireless Devices	142	
7.4	Considerations	142	
7.5	Hospital Costs of Information Management	143	
7.6	Other Information Processing Capabilities	143	
8.	Competitive Assessment of High-Growth Markets	144	
8.1	Glucose Monitoring	144	
8.1.1	Overview of Market Segment	144	
8.1.2	Competitive Strategies	145	
8.1.3	Analyses of the Current Market Conditions, Competition and Product Mix	146	
8.1.4	New Approaches to the Glucose Data Management Marketplace	147	
8.1.5	How Each Company is Losing/Gaining Market Share	147	
8.1.6	Partnering Opportunities with Complementary Third-Party Products	147	
8.1.7	Adjacent Markets	148	
8.2	Tumor Markers	148	
8.2.1	Overview of Market Segment	148	
8.2.2	Competitive Strategies	148	
8.2.3	Analyses of the Current Market Conditions, Competition and Product Mix	149	
8.2.4	Adjacent Markets	152	
8.3	Cardiac Care	152	
8.4	Infectious Disease	153	
8.4.1	Overview of Market Segment	153	
8.4.2	Competitive Strategies	153	

8.4.3	Analyses of the Current Market Conditions, Competition and Product Mix	154
8.4.4	New Approaches to the Infectious Disease Marketplace	154
8.4.5	The Impact of Molecular Diagnostic Methods on the Diagnosis of Infectious Disease	154
8.4.6	Partnering Opportunities with Complementary Third-Party Products	155
8.4.7	Emerging Viral Infections	156
8.5	Coagulation	156
8.6	Drugs of Abuse Testing/Therapeutic Drug Monitoring	156
9.	Market Trends and Forecasts	158
9.1	Home Care Analysis	158
9.2	Non-traditional Collection for POC Testing	158
9.3	New Systems for Critical Care and Near-Patient Testing	158
9.4	Utility of Near-Patient Testing in Critical Care Settings	158
9.5	Mergers of Diagnostic Companies	158
9.6	Information Management Advances	158
9.7	Test Ordering Patterns	158
9.8	Patient Satisfaction	158
9.9	Move Away from Central Laboratory	159
9.10	Healthcare Cost Controls	159
9.11	Future of POC Testing	159
9.12	Biotechnology Industry Trends	159
9.13	Pharmaceutical Industry Trends	160
9.14	Acquisition, License Agreement, Partnerships	160
10.	Corporate Profiles	161
10.1	LabCorp	161
10.2	Lifescan, Inc.	162
10.3	OraSure Technologies, Inc.	162
10.3.1	OraSure Collection Device	162
10.3.2	OraQuick Rapid Test	162
10.3.3	UPT	162
10.3.4	Histofreezer	163
10.3.5	Immunoassay Tests and Reagents	163
10.4	Bayer Corp.	163
10.4.1	Background	163
10.4.2	Business Analysis	164
10.5	MediSense	166
10.6	i-STAT Corp.	166
10.7	Nova Biomedical	167
10.7.1	Introduction	167
10.7.2	Electrolyte and Blood Gas Analyzers	167
10.7.3	Business Analysis	168
10.8	Wyntek Diagnostics	169
10.9	Savyon Diagnostics	169
10.10	Spectral Diagnostics	170
10.11	Biosite Diagnostics	170
10.12	Abbott Laboratories	173
10.12.1	Background	173
10.12.2	Key Opportunities in Rapid Tests	173
10.12.3	Business Analysis	174
10.13	Wampole Laboratories	175
10.14	Beckman Coulter Diagnostics Corp.	175
10.15	Instrumentation Laboratory	176
10.16	MedMira Laboratories	176
10.17	Radiometer	177
10.17.1	Background	177

10.17.2	Instrumentation	177	
10.17.3	Business Analysis	178	
10.18	GenBio	178	
10.19	Ely labs	178	
10.20	Orgenics	179	
10.21	bioMérieux Vitek, Inc.	179	
10.22	ANI Biotech	179	
10.23	Sybron International Corp.	180	
10.24	Optical Sensors, Inc.	180	
10.25	Worldwide Medical Corp.	181	
10.26	International Medical Innovations (IMI)	181	
10.27	Cardiovascular Diagnostics	181	
10.28	Abaxis, Inc.	181	
10.29	Inverness Medical Innovations	183	
10.29.1	Consumer Products	183	
10.29.2	Clinical Diagnostic Products	184	
10.30	ChemTrak, Inc.	184	
10.30.1	The AccuMeter Cassette System	184	
10.30.2	The Home Test Service	185	
10.30.3	Parent's Alert Home Drug Test Service	185	
10.30.4	CholesTrak Home Cholesterol Test	185	
10.30.5	Sales and Marketing	185	
10.30.6	Competition	186	
10.31	Cholestech	187	
10.31.1	Diagnostic Products	187	
10.31.2	WellCheck	187	
10.32	HemoCue, Inc.	188	
10.33	Binax Corp.	188	
10.34	Selfcare	188	
10.35	Johnson & Johnson	189	
10.36	Accumetrics	189	
10.37	First Medical, Inc.	189	
10.38	Response Biomedical Corp.	189	
10.39	Compucyte Corp.	190	
10.40	Caliper Technologies	190	
10.41	Princeton BioMeditech	190	
10.42	American Biogenics Sciences	190	
10.43	New Horizons Diagnostics	191	
10.44	Beacon Diagnostics	191	
10.45	Saliva Diagnostics	191	
10.46	Calypte Biomedical Corp.	192	
10.46.1	The Calypte Urine-Based HIV-1 Screening and Supplemental Tests	192	
10.46.2	The Cambridge Biotech Serum-Based HIV-1 Supplemental Test	192	
10.46.3	The Sentinel Testing Service	192	
10.46.4	HIV Viral Lysate Stock	193	
10.47	Meridian Diagnostic	193	
10.48	Quidel	195	
10.49	Biomerica	195	
10.50	Diagnology, Inc.	196	
10.51	BioStar (Thermo Electron Corp.)	196	
10.52	ActiMed Diagnostics	196	
10.53	Empyrean Diagnostics	197	
10.54	STC Technologies	197	
10.55	Trinity Diagnostics	197	
10.56	Genzyme Diagnostics	198	
10.57	ImmunoScience, Inc.	198	



10.58	Cygnus Therapeutic Systems	199
10.58.1	The GlucoWatch System	199
10.58.2	GlucoWatch G2 Biographer	199
10.58.3	Partnerships	200
10.59	Seradyn Clinical Diagnostics/Apogent Technologies	201
10.60	Adeza Biomedical Corp.	201
10.61	Array Medical	202
10.62	Transmedica	202
10.63	BioScan Screening Systems, Inc.	202
10.64	American Bio Medica Corp.	202
10.65	GDS Technology	203
10.66	Home Access Health Corp.	203
10.67	Pharmatech Corp.	204
10.68	Thoratec/International Technidyne Corp.	204
10.69	SpectRx, Inc.	204
10.70	Helena Laboratories	205
10.71	Technical Chemicals & Products	205
10.72	Roche Diagnostics	206
10.73	Simplex Medical Systems	208
10.74	Biex, Inc.	208
10.75	POC Technologies	208
10.76	LXN Corp. (Inverness Medical Technologies)	209
10.77	American Biogenetic Sciences, Inc.	209
10.78	Lifestream Technologies	209
10.79	PanBio Corp.	210
10.80	Phillips Medical Systems	210
10.81	Jiangnan Biotech	211
10.82	MiniMed	211
10.83	Meretek Corp.	212
10.84	Avox Systems	212
10.85	Dade Behring	212
10.86	Chongqing Sungene Pharmaceutical Co., Ltd.	213
10.87	Medical Services International, Inc.	213
10.88	Therasense, Inc.	213
10.89	PharmaNetics, Inc.	213
10.90	Shanghai SIIC Kehua Biotech Co., Ltd. (Kehua Biotech)	214
10.91	LifePoint, Inc.	214
10.92	Avitar, Inc.	214
10.93	Cozart Biosciences	215
10.94	Enterix, Inc.	215
10.95	Kyowa Medex Co., Ltd.	215
10.96	Iatron	215
10.97	Denka Seiken Co., Ltd.	215
10.98	Accurex Biomedical, Pvt., Ltd.	215
11.	Corporate Directory	216

## INDEX OF FIGURES

Figure 1: Serological and Clinical Course of Acute HBV Infection	73
Figure 2: Time Course of Serologic Markers in Acute Hepatitis C Infection	76

## INDEX OF TABLES

Table 1: Ten Largest Diagnostic Companies Worldwide Revenues and Market Share 2000	19
Table 2: Total Clinical Diagnostics Dollar Volume by Market Segment 2000	20
Table 3: U.S. Market for Clinical Chemistry Dollar Volume by Analyte 2000	21
Table 4: Worldwide Market for Clinical Chemistry Dollar Volume by Analyte 2000	22
Table 5: Worldwide Market for Other Immunoassays Dollar Volume by Analyte 2000	22
Table 6: Worldwide Market for Nucleic Acid Assays for Infectious Disease Dollar Volume by Analyte 2000	23
Table 7: Worldwide Market for Other Nucleic Acid Arrays Dollar Volume by Analyte 2000	23
Table 8: Market for Coagulation Tests Dollar Volume by Region 2000	24
Table 9: Market for Critical Care Tests Dollar Volume by Region 2000	24
Table 10: U.S. Alternate Site Diagnostic Test Dollar Volume by Sector	26
Table 11: U.S. Clinical Diagnostic POC Testing and Rapid Test Market Segments Dollar Volume	27
Table 12: Number of Sites by Type Doing In Vitro Diagnostic Testing in the U.S.	27
Table 13: U.S. Clinical Laboratory Testing Services Revenue and Growth Rates by Segment	28
Table 14: U.S. Doctor's Office Test Market Revenue and Growth Rate by Segment	28
Table 15: U.S. Clinical Diagnostic Home Test Market Revenue and Growth Rates by Segments 1999	28
Table 16: U.S. In Vitro Diagnostic Testing Including Reagents, Instruments, Consumables and Controls Total Sales by Segments 1999	29
Table 17: Global Diabetic Population 1995 and 2025 30	
Table 18: Worldwide POC Glucose Testing Market Dollar Volume and Growth Rate	31
Table 19: U.S. Market for POC and Near-Patient Blood Glucose Testing Market Share by Company	31
Table 20: World Market Share of POC Glucose Monitoring Marketers	31
Table 21a: Worldwide Market for Rapid Coagulation Testing Dollar Volume 2000-2008	38
Table 21b: U.S. Market for Rapid Coagulation Testing Dollar Volume 2000-2008	38
Table 21c: U.S. Market for Rapid Coagulation POC Testing Dollar Volume 1996-2007	38
Table 22: U.S. Market for POC Cardiac Marker Testing Dollar Volume and Growth Rate 1999-2007	44
Table 23: Drugs of Abuse Screening U.S. Market Size 1998-2007	53
Table 24: National Institute on Drug Abuse Screening Standards Cutoff Levels by Drug and Test Method	55
Table 25: U.S. POC Drugs of Abuse Testing Market 2001-2007	56
Table 26: Serological Diagnosis of Hepatitis B Virus Infections	74
Table 27: Lower Detection Limits of HBV DNA Assays	75
Table 28: U.S. and Global Market for HAV Diagnostic Testing	81
Table 29: U.S. and Global Market for HBV Diagnostic Testing	81
Table 30: U.S. and Global Market for HCV Diagnostic Testing	82
Table 31: Current Assays for HIV Viral Load Testing	93
Table 32: U.S. and World Markets for HIV Diagnostic Testing	94
Table 33: U.S. Cholesterol Testing Volume 2000-2007	99
Table 34: Worldwide Market for In Vitro Cancer Marker Products Dollar Volume in 1999 and 2007	102
Table 35: U.S. Market for Tumor Marker Assays Dollar Volume by Marker 1998-2002	103
Table 36: Comparison of Costs at "Moderately Complex" and "Waived" CLIA Labs	115
Table 37: CPT Codes and Reimbursement Amount for Selected Tumor Markers New York and California	119
Table 38a: POC Testing Versus Laboratory Testing Clinical Outcomes in Diabetic Ketoacidosis	121
Table 38b: POC Testing Versus Laboratory Testing Clinical Outcomes in ABG Measurements	121
Table 39: Emergency Room Admissions in the U.S.	122
Table 40: POC Testing Cost Analysis with Labor Included	123
Table 41: Cost Analysis for Glucose Testing: POCT versus Central Lab	123
Table 42: Normal Blood Glucose Values in Fasting State and Two Hours Postprandially	131
Table 43: Applications for Wireless LAN Technology Present and Future	141
Table 44: Wireless Hospital Network Access Points Technology Prices Access Points	143
Table 45: Wireless Hospital Network Access Points Technology Prices Desktop Adapters (One Computer)	143
Table 46: Wireless Hospital Network Access Points Technology Prices PCMCIA Adapters	143

## 1. Overview

### 1.1 Objectives

The purpose of this report is to describe the specific segments of the *in vitro* diagnostics market that are believed to have the potential for exceptionally high growth over the next five years. It examines those clinical measurement devices and their reagents and supplies that are utilized in hospitals, clinics and doctor's offices—as well as by patients—to diagnose and monitor disease.

### 1.2 Content and Scope

This report reviews the high-growth market segments for clinical laboratory testing equipment and supplies in the clinical hospital market, using screening reagents and instruments for analysis of individual components in blood, serum or plasma. Further, it examines the subsections of each market segment, including the clinical laboratory and research areas. Activity and trends in the clinical diagnostic market are discussed, including the numbers of institutions using this type of testing, and the factors that influence purchasing activity. Discussion details the trends that have developed that stimulate this market, and offers detailed comments on the patterns of information processing in point-of-care (POC) testing instruments.

The report surveys most of the important companies known to be marketing, manufacturing or developing instruments and reagents in the areas selected as high-growth diagnostic markets in the U.S. Each company is discussed in depth, with a section on its history, product line, business and marketing analysis, and a subjective commentary on the company's position in its market and its strategic direction.

Certain areas are only touched upon in this report. While these areas are related to the major elements of this report, they are in themselves an entirely different field or market. For example, the clinical chemistry testing market, or hematology, forms the foundation of much clinical screening testing today, but in the interest of brevity this area was not analyzed in depth.

The emphasis in this report is on those companies and products that are actively developing and marketing clinical laboratory instrumentation and reagents and supplies in market segments, and which have the potential for growth rates above 15% per year over the next five years. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for a detailed discussion of the important individual market segments that are related to these high-growth markets, such as *POC Diagnostic Testing World Markets*, *Over The Counter Diagnostic Products World Markets* and *Cancer Diagnostic Testing World Markets*. The diagnostic markets that TriMark identified as candidates for exceptionally high annual growth rates over the next five years can be divided into eight general areas:

- Glucose monitoring.
- Rapid coagulation testing.
- Rapid cardiac markers.
- Drugs of abuse screening testing.
- Infectious disease testing.
- Cholesterol testing.
- Hepatitis testing.
- Tumor markers.

Concentration of this analysis is placed upon the overview of individual diagnostic markets that TriMark believes possess the elements that will lead to high and sustained growth rates for the foreseeable future. It assesses the current status of each market, makes five-year projections for market size, discusses the market strategies of the leading companies in each market segment, and evaluates the forces that underlie the high growth of each segment. Also presented is a brief description of the instruments, reagents and supplies marketed by major companies in each market segment. Discussion involves the market size, growth rate and market components for instruments, reagents, controls and consumables used in each high-growth area.

The report does not cover slower growing and relatively mature diagnostic markets such as hematology, although many of the instruments, reagents and techniques in the high-growth testing market segment are intimately associated with these broader areas. It does touch on the specialty testing areas in each high-growth market, since these segments are frequently a part of the overall analytical focus of companies marketing general laboratory automation equipment. However, no effort is made to quantify the size of this broader market; the report also doesn't focus on well-known companies that market and sell a limited number of instruments and equipment in a particular important diagnostic segment as a part of a much larger clinical laboratory product line. For example, Johnson & Johnson, Roche Diagnostics, Bayer Diagnostics and others who market many tests and instruments as part of their clinical line of reagents are discussed less in detail than some rather less well-known companies, which are smaller but market promising new *in vitro* diagnostic products.

In addition, there are a number of companies that market diagnostic testing devices, particularly urine test strips and occult blood test kits, which are primarily distributors of these products rather than the primary developer. These companies, although necessary and important to the diagnostic testing industry, are not covered in this report. This report discusses business trends, patient issues, technology trends and specific issues regarding growth drivers in diagnostic testing.

This report does not discuss clinical laboratory robotics and automation in detail. Although this report mentions recombinant proteins in passing, as well as techniques such as measuring the serum concentrations of therapeutic drugs and drugs of abuse, no extensive or in-depth treatment of this subject is presented. Such a discussion is outside the scope of this report but is covered in detail in TriMark's *Genomics World Markets* report and *Cancer Diagnostic Testing World Markets* reports. Each corporate profile includes the following elements:

- History.
- Unique company strengths.
- Corporate research and development strategy.
- Intellectual property assessment.
- Corporate collaborations.
- Products and developmental pipeline.
- Discovery-stage projects.
- Summary assessment of market prospect.
- Direct pipeline competition.
- Potential improvements over existing products.
- Financial details.
- Summary.

This report updates the current status and future potential of the market for *in vitro* diagnostics worldwide, concentrating on areas that are seeing significant change and substantial future growth worldwide. It is an invaluable source of competitor information for executives and decision-makers in diagnostic companies.

### 1.3 Methodology

The information in this report is based upon interviews with sales and marketing professionals of companies in the clinical laboratory market. People from virtually every company mentioned in this report were queried, some several times, about their company's products and marketing strategies, as well as their overall thoughts about their industry segment. Interviews with founders, CEOs and vice presidents of some of the companies discussed in the report also provided information. The structure of the hospital laboratories and near-patient facilities was derived from interviews with laboratory directors and medical technologists working in these areas.

Other sources of information included trade association publications and meetings, product brochures and catalogs, and company literature. When publicly-held companies were discussed, an examination of the annual reports, 10k filings and financial reports were used as the basis of the data reported. Some of the information obtained for the report was taken from TriMark's databases, Biotechnology Associates' data files and from the private data stores of the author. Much of the tabular data in this report have been developed from primary company sources with the help of a proprietary database calculator. The information set forth in this study was obtained from sources that TriMark

believes to be reliable, but it does not guarantee its accuracy, adequacy or completeness of any information or omission, or for the results obtained by the use of such information.

#### 1.4 Executive Summary

TriMark estimated the worldwide *in vitro* medical diagnostic testing market to have been slightly more than \$ [REDACTED] in [REDACTED]. This figure encompasses all aspects of clinical laboratory testing, including central testing in hospitals and commercial labs, and alternate site testing (including POC, doctor's office, corporate and clinics), but excluding home care or over-the-counter (OTC) testing. The U.S. is the largest single market segment, with an annual product sales value estimated to be almost \$ [REDACTED].

Geographically, North America accounts for about [REDACTED]% of the total *in vitro* diagnostic (IVD) testing market of all types. The remaining diagnostic testing volume is generally divided between Europe at [REDACTED]%, Japan at [REDACTED]% and the rest of the world at [REDACTED]%. Total IVD revenues are growing at about [REDACTED]% per year worldwide, while the underlying test volume is growing at [REDACTED]% per year. The difference in these numbers suggests the price pressures in the industry.

In the market segment of general clinical chemistry, TriMark believes that the glucose whole blood testing segment is still a high-growth area despite its rather mature status in the hospital critical care areas. TriMark finds that there is still a substantial growth potential in the clinic and in-home testing, driven by the high prevalence of diabetes as a major health risk throughout the world.

In the U.S., the current glucose testing market is estimated to be \$ [REDACTED], with a worldwide market of \$ [REDACTED]. TriMark believes that the U.S. market is still growing at a rate of between [REDACTED]% and [REDACTED]%, primarily due to replacement units and more sophisticated data processing. Worldwide, there is still much room for expansion, and TriMark sees the market as growing by [REDACTED]% to [REDACTED]% over the next [REDACTED] years.

In [REDACTED], the worldwide market for immunoassays exceeded \$ [REDACTED], consisting primarily of testing related to infectious disease, endocrinology, therapeutic drug monitoring, drugs of abuse testing, immunology/allergy, tumor markers and blood typing. The global market for immunoassays continues to expand as new disease states are identified, new therapies become available, and worldwide standards of living and access to healthcare improve. Such tests are performed primarily in hospital-based laboratories and commercial laboratories, which account for approximately [REDACTED]% of all diagnostic tests performed annually. In recent years, diagnostic tests that can be performed nearer to the point of patient care have emerged as an important tool in disease diagnosis and management.

A relatively small share of this \$ [REDACTED] worldwide diagnostics market is represented by the high-growth areas selected for this report. The POC area certainly is, although much of this segment is still very closely tied to hospital practice. A substantial part of glucose testing might be included in this site segment, particularly the doctor's office and group practice markets. But much of the glucose testing still occurs in hospitals. In addition to the direct diagnostic utility of *in vitro* tests, some of the key major trends that will continue the growth of the industry are:

- Global demographics.
- Healthcare delivery and disease management.
- Technologic innovation.

In the U.S., approximately [REDACTED]% of clinical diagnostic testing is currently conducted in hospital-based and commercial laboratories. The alternate site diagnostic testing in [REDACTED] represented [REDACTED]% of the \$ [REDACTED] U.S. market for clinical diagnostic testing reagents, controls and equipment, and is projected to grow at an annual rate of [REDACTED]% through [REDACTED]. This estimate of the \$ [REDACTED] alternate site diagnostic testing market comprises both the traditional hospital-oriented POC testing and the newer elements of the free-standing clinic, doctor's office testing, doctor's group testing, corporate screening, but not home and OTC testing. This latter segment will become an increasingly larger and important part of the overall IVD testing picture in the next [REDACTED] years.

The IVD industry was estimated to grow to \$ [REDACTED] worldwide by the end of [REDACTED]. This figure encompasses all aspects of clinical laboratory testing, including central testing in hospitals and commercial labs, alternate site testing (including POC, doctor's office, corporate and clinics), except home care or OTC testing. Some areas of this industry are relatively stable (*e.g.*, serum enzyme testing), but others are due for explosive growth (*e.g.*, tumor



markers, hepatitis testing, drug testing, infectious disease testing and cardiac markers). The U.S. is the largest single market segment, with an annual product sales value estimated to be almost \$ [REDACTED]. Overall, the U.S. hospital-based POC market was estimated by TriMark to be about \$ [REDACTED] in sales. The total rapid, near-patient *in vitro* U.S. diagnostic testing market is \$ [REDACTED]. The second part of the alternate site diagnostic testing segment consists of physician office labs (POLs), nursing homes, pharmacies and other non-institutional settings in which healthcare providers perform diagnostic tests. This market segment is estimated to be about \$ [REDACTED]; clinics are \$ [REDACTED]; and miscellaneous other testing is \$ [REDACTED]. This market segment is growing at [REDACTED] % per year.

There were approximately [REDACTED] hospital labs certified for clinical laboratory improvement amendments (CLIA) in the U.S. in [REDACTED]. Since there are only [REDACTED] hospitals in the U.S., some of these are probably ancillary testing sites within the main facility. There are [REDACTED] independent labs in the U.S., and [REDACTED] POLs registered with CLIA. There are [REDACTED] labs of all types in the U.S. registered with CLIA. The difference between the number of "all types" and the number of POL, independent, hospital-registered labs and all types is [REDACTED], which includes clinics, drawing stations, corporate sites and other miscellaneous diagnostic testing providers in the U.S.

The third part of the alternate site diagnostic testing market is generally considered to be the at-home market. The OTC self-test market in the U.S. was estimated by TriMark to be north of \$ [REDACTED] in [REDACTED]. The OTC market is growing at a rate of [REDACTED] % per year. In the U.S., revenues from home diagnostic products and monitoring devices grew at a rate of [REDACTED] % compounded annually from \$ [REDACTED] in [REDACTED] to \$ [REDACTED] in total revenues in [REDACTED]. TriMark forecasts double-digit growth through [REDACTED] to \$ [REDACTED]. Much of this growth is expected to come from easy-to-use, POC diagnostic tests.

#### 1.4.1 Glucose Monitoring

Worldwide sales of blood glucose self-monitoring products (home and OTC) were approximately \$ [REDACTED] in [REDACTED], which represented an increase of approximately [REDACTED] % over [REDACTED] levels. The finger-stick blood glucose testing market is estimated to be growing at [REDACTED] % annually. The blood glucose monitoring POC segment is by far the largest of the alternate site diagnostic testing market segments, and this is the driver for more growth. The world market is very mature, with annual sales in [REDACTED] of \$ [REDACTED], and growing at a rate of [REDACTED] % to [REDACTED] % per year. The market grew to \$ [REDACTED] by [REDACTED]. The annual growth of the glucose testing market is in the range of [REDACTED] % to [REDACTED] % annually. The POC glucose testing market is projected to grow to \$ [REDACTED] by [REDACTED].

#### 1.4.2 Coagulation

This is a difficult market segment to evaluate. There are actually several markets for coagulation type testing (APTT, PTT, D-dimer, etc), as well as the large prothrombin time (PT) segment. Furthermore, there is a projected home or patient market and a professional segment in PT testing. This is further complicated by the different assumptions on frequency of testing that drives the potential market. The total coagulation testing market worldwide was estimated to be \$ [REDACTED] in [REDACTED], with the U.S. share at \$ [REDACTED]. The total coagulation market worldwide and in the U.S. is growing at [REDACTED] % per year, and is projected to reach \$ [REDACTED] by [REDACTED] (see Table 21). The total U.S. coagulation market is growing at [REDACTED] % per year and was \$ [REDACTED] in [REDACTED], growing to \$ [REDACTED] in [REDACTED].

TriMark estimates that the U.S. market for rapid, POC-type coagulation tests is approximately \$ [REDACTED] and growing at a rate of [REDACTED] % per year (see Table 21). The total sales for [REDACTED] were \$ [REDACTED], increasing to \$ [REDACTED] in the U.S. in [REDACTED]. This is the highest growth rate of all of the segments in the rapid test area, save cardiac tests, but moves from a much higher base of sales than the latter. There has been double-digit growth for these markers in the U.S. The market for D-dimer alone has been estimated by TriMark to be over \$ [REDACTED] in the U.S., and is expected to grow at [REDACTED] % per year.